Sep, 2012

U.S.A.
News / Therapeutic Area News
U.S. FDA Approves XTANDI® (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel
San Francisco, CA and Tokyo – August 31, 2012 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA)...
Read More
U.S.A.
News / Therapeutic Area News
Full Prescribing Information for XTANDI (enzalutamide) Capsules
Full Prescribing Information for XTANDI (enzalutamide) Capsules
Read More
U.S.A.
News / Therapeutic Area News
PATIENT INFORMATION XTANDI® (ex TAN dee) (enzalutamide) capsules
Read this Patient Information before you start taking XTANDI and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare...
Read More

Aug, 2012

U.S.A.
News / Therapeutic Area News
New England Journal of Medicine Publishes Results from Phase 3 AFFIRM Trial of Enzalutamide
San Francisco, CA and Tokyo – August 15, 2012 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced the publication in the New England Journal of...
Read More
U.S.A.
News / Therapeutic Area News
Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA
San Francisco, CA and Tokyo – August 3, 2012 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has...
Read More